Runge-Morris M A, Kies M S, Vokes E, Blough R, Weidner L, Knop R, Rowland K
Department of Pharmacology, Northwestern University Medical School, Chicago Illinois.
Invest New Drugs. 1989 Jul;7(2-3):269-73. doi: 10.1007/BF00170872.
Eighteen patients entered this study of the efficacy of homoharringtonine (HHT) treatment in advanced squamous cell carcinoma of the head and neck (SCCHN). Seventeen eligible patients received at least one day of the first 5-day cycle of HHT (4.0 mg/m2/day) by continuous IV infusion. Cycles were scheduled to repeat every 28 days. The major severe toxicities encountered were hypotension and myelosuppression. There was one drug-related death. Fourteen patients were evaluable for response, and no patient exhibited an objective response to treatment with HHT.
